1Steinbrook R. Guidance for guidelines. N Engl J Med, 2007, 356 : 331-333.
2Armstrong PW, Newby LK, Granger CB, et al. Lessons learned from a clinical trial. Circulation, 2004, 110:3610-3614.
3The House of Commons Health Committee, The Influence of the Pharmaceutical Industry, Volume 1. April 5, 2005, p. 55. Available from : http ://www. parliament.the-stationery-office.co.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf, accessed 6/ 08/05.
4Relman AS, Angell M. America's other drug problem: how the drug industry distorts medicine and politics. New Republic, 2002,587:27-41.
5Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ, 2003,326 : 1167-1170.
6Barnett A, Revealed: how drug firms 'hoodwink' medical journal. Pharmaceutical giants hire ghostwriters to produce articles-then put doctors' names on them. The Observer, 2003 Dec 7.
7Abramson J, Starfield B. The effect of conflict of interest on biomedical research and clinical practice guidelines: Can we trust the evidence in evidence-based medicine? J Am Board Fam Pract, 2005,18 : 414-418.
8Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. JAMA, 2000,284 : 1247-1255.
9Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The VIGOR study group. N Engl J Med, 2000,343 : 1520-1528.
10American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum, 2000,43 : 1905-1915.
